No published figure describes how long compounded tirzepatide lasts. The beyond-use date printed by the pharmacy that prepared the vial is the only one that applies, and it applies to that vial alone. Symptoms are not a substitute for it. Nausea says very little about a preparation’s condition, while injection site reactions and measuring mistakes say considerably more.
Start with what the date actually is
An approved medicine reaches a pharmacy shelf with an expiration date grounded in manufacturer stability testing reviewed by FDA. Compounded preparations sit outside that process. FDA does not evaluate compounded drugs for safety, effectiveness or quality before they are marketed, and dating is assigned by the pharmacy that built the preparation under the standards covering its category. Concentration, excipients and preservative status differ between pharmacies, so no two products carry interchangeable dating.
That leaves patients trying to read their own bodies for information the body cannot provide. It is worth being blunt about the limits of that approach before working through what individual symptoms mean.
None of that is knowable from a public database, so patients are left comparing what each provider is willing to explain up front. The range is wide. Henry Meds and Hims & Hers frame their offers around access and convenience, LillyDirect points to the branded product, and a service like HealthRX maintains reference material on compounded tirzepatide that names the handling and dating steps involved. A provider that will put those details in writing is easier to hold to them later.
Effects that belong to the drug class
Gastrointestinal complaints dominate the safety picture for approved dual GIP and GLP-1 receptor agonist therapy. In the obesity trial program for tirzepatide, nausea, diarrhea, vomiting and constipation were the effects reported most often, generally around dose increases and generally easing over time. The same pattern appears in the sleep apnea trial in adults with obesity. Emergency medicine reviews of this drug class describe the same cluster arriving at the front door.
None of that distinguishes a fresh vial from an old one. A perfectly good preparation produces those effects, and so does a degraded one. Reasoning backward from queasiness to product condition does not work in either direction.
Signals that point at the product rather than the molecule
Some presentations do carry information. FDA has described a reported adverse event linked to a product labeled as compounded tirzepatide from a pharmacy that did not make it, involving redness, swelling and pain at the injection site along with a red lump. Localized reactions that are new, spreading, or accompanied by fever belong in a different mental bucket than nausea, because they raise questions about sterility and product identity rather than pharmacology.
European pharmacovigilance analysis of counterfeit semaglutide reports and pharmacovigilance work on compounded GLP-1 products using the FDA adverse event system both point in the same direction: the harms that separate unapproved supply from approved supply cluster around what was actually in the syringe, not around the expected profile of the active ingredient.
Measuring errors are the documented failure mode
The clearest signal in the published record is not slow chemical decay. It is people injecting the wrong amount. FDA has received multiple adverse event reports, some involving hospitalization, that may relate to dosing errors with compounded injectable semaglutide, arising from patients measuring and self-administering incorrect amounts and in some cases from health care professionals miscalculating. A poison control center case series documented the same category of error. Reported symptoms in the FDA account included nausea, vomiting, diarrhea, abdominal pain and constipation, sometimes serious enough that people sought care.
This matters for shelf life questions because a vial reaching its date often coincides with improvisation. Somebody tries to make the remainder go further, or draws from a container whose contents no longer match the assumption the plan was built on.
| What is happening | Most likely reading | Where it belongs |
|---|---|---|
| Nausea or constipation after a dose increase | Class effect seen throughout the approved trial program | Routine, worth mentioning at the next check-in |
| Severe vomiting, dehydration, or abdominal pain that will not settle | Reported in FDA accounts of dosing errors | Same-day medical attention |
| New redness, swelling, pain or a lump at the injection site | Raises sterility and product identity questions | Call the prescriber promptly, keep the vial |
| Fever or spreading warmth around the site | Possible infection, not a pharmacology effect | Urgent care, do not wait it out |
| Nothing at all, on a vial past its date | Reassuring in appearance only | Still a call to the pharmacy, not a green light |
| Effect seems weaker than before | Unreliable as evidence about potency | Discuss with the prescriber before changing anything |
Why fading effect is a bad detector
Appetite response varies week to week for reasons that have nothing to do with the vial: illness, sleep, stress, food environment, and the natural course of treatment. Reading potency out of that noise is not possible. Degradation of peptide products meanwhile proceeds through chemical routes that produce no visible or felt signal, which is exactly why laboratory analysis rather than self-observation is how these questions get settled.
The financial pressure behind the question deserves a straight answer too. Replacing a vial costs money, and the temptation to stretch one appears at precisely the moment the budget is tightest. Published cash pricing from supervised providers such as Ro, Mochi Health and formblends.com makes the replacement cost knowable in advance, and knowing it in advance is what keeps the decision away from the point of injection. Manufacturer channels including LillyDirect are worth pricing at the same time, since eligibility and coverage change.
Who to call, in what order
Anything that looks like infection or severe dehydration is a medical question first and a product question second. Once care is arranged, the dispensing pharmacy holds the lot and formulation record and should hear about it. Adverse events and quality problems can also go to FDA through MedWatch, which matters because state-licensed pharmacies outside the outsourcing facility category are not federally required to report adverse events, leaving the picture thinner than it should be.
Frequently asked questions
Can nausea tell me my vial has gone off?
No. Nausea, vomiting, diarrhea and constipation were the most commonly reported effects in the approved tirzepatide trial program, and they occur with product in perfect condition. Using them as a quality indicator produces false alarms in both directions. The labeled date and the pharmacy that set it remain the reference.
What symptom should move fastest?
Anything suggesting infection at the injection site, such as spreading redness, warmth, or fever, along with vomiting severe enough to threaten hydration. Those need medical attention the same day. Keep the vial and its packaging, because the lot number is what allows the pharmacy and FDA to trace a problem.
If I feel completely fine, is a past-date vial acceptable?
Feeling fine is not evidence about sterility, potency or degradation products. FDA has stated that poor compounding practices can produce contamination or incorrect amounts of active ingredient, neither of which announces itself. The absence of symptoms after one dose says nothing about the next one.
Why do dosing errors keep appearing in this category?
Because compounded products come in varying concentrations and presentations, and the arithmetic shifts with each one. FDA has reported adverse events tied to patients and clinicians miscalculating amounts with compounded semaglutide and tirzepatide, some serious. Any change in product, pharmacy or concentration is a moment to re-confirm the plan with the prescriber.
Should a reaction be reported if it resolved on its own?
Yes. Reporting builds the record that regulators use to spot patterns, and the record for compounded products is known to be incomplete because most state-licensed compounding pharmacies have no federal adverse event reporting requirement. A resolved reaction with a lot number attached is still useful information.
